GlassScriptPhysician profile
Marlan D Kay
NPI 1619175155
$1,341.36
in general payments reported to CMS, 2019-2025
23 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.36 · 2020: $137 · 2021: $127 · 2022: $168 · 2023: $209 · 2024: $442 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $231.97 | 2020-2024 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $184.25 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Abbvie INC. | $144.05 | 2021-2024 | |
| Microvention, INC. | $79.54 | 2019-2024 | Azur Cx Detachable |
| Novartis Pharmaceuticals Corporation | $76.46 | 2020-2024 | |
| Acadia Pharmaceuticals INC | $71.48 | 2024 | Nuplazid |
| Lilly USA, LLC | $63.01 | 2022-2024 | Kisunla, Emgality, Reyvow |
| Genzyme Corporation | $52.49 | 2021-2022 | |
| Mdd US Operations, LLC | $52.42 | 2025 | Gocovri |
| Neurocrine Biosciences, INC. | $46.07 | 2023-2024 | Ingrezza, Ongentys |
| Octapharma USA, INC. | $43.13 | 2022 | |
| Amneal Pharmaceuticals LLC | $40.85 | 2022-2023 | Rytary |
| Tg Therapeutics, INC. | $33.96 | 2023 | |
| Janssen Biotech, INC. | $30.58 | 2025 | |
| Alnylam Pharmaceuticals INC. | $28.30 | 2025 | Amvuttra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $25.59 | 2019 | |
| Ucb, INC. | $24.00 | 2020 | |
| Boston Scientific Corporation | $23.30 | 2025 | Vercise |
| Acorda Therapeutics, INC | $22.94 | 2022 | |
| Csl Behring | $18.84 | 2025 | Hizentra |
| Celgene Corporation | $18.58 | 2022 | |
| Allergan, INC. | $15.58 | 2021 | |
| Neurelis, INC. | $13.97 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlan Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.